Autoantibody Detection for Autism Spectrum Disorder Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack effective tools for identifying and predicting the risk of neurodevelopmental disorders, such as autism spectrum disorders, and there is no genetic or biologic test available for diagnosing these conditions, hindering early intervention and understanding of their etiology.
Innovation Solution
The development of methods to determine the presence of autoantibodies against neural antigens in individuals and detecting specific patterns of brain region and cell type binding, using techniques like immunoblotting and immunohistochemistry, to identify markers indicative of neurodevelopmental disorders, including autism spectrum disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for neurodevelopmental disorders, then the diagnostic process relies on behavioral observations and clinical criteria, but there is no objective biologic test available to definitively diagnose or predict risk
Solution Approach 1:
The patent replaces subjective behavioral observation and clinical assessment with objective immunological testing. Autoantibody detection using immunoblotting and immunohistochemistry provides a biologic marker-based diagnostic system that substitutes mechanical/behavioral evaluation with biochemical measurement, enabling definitive diagnosis through detection of autoimmune responses against neural antigens
Solution Approach 2:
The patent introduces autoantibodies as intermediary biomarkers that mediate between the underlying autoimmune pathology and the clinical manifestation of neurodevelopmental disorders. These autoantibodies serve as detectable intermediaries that link the immune system's response to neural tissue damage with the behavioral and cognitive symptoms of ASD and related disorders
2Loss of time
If early intervention is desired for neurodevelopmental disorders, then diagnostic testing should be available before symptom onset, but current methods cannot predict risk in individuals or offspring
Solution Approach 1:
The patent enables preliminary detection of autoimmune markers before clinical symptoms manifest. By testing for autoantibodies against neural antigens in at-risk individuals and offspring, the system allows early identification of those who will develop neurodevelopmental disorders, enabling preventive or early intervention strategies before irreversible damage occurs
Solution Approach 2:
The patent establishes a feedback mechanism where autoantibody detection results provide information about an individual's risk status, which then guides further diagnostic evaluation and intervention decisions. The presence or absence of specific autoantibody patterns feeds back into the diagnostic process, allowing clinicians to adjust their approach based on objective biomarker data
3Loss of information
If the etiology of neurodevelopmental disorders is to be understood, then research needs to identify specific immune mechanisms, but the role of immune dysfunction remains hypothetical without objective markers
Solution Approach 1:
The patent uses immunohistochemical staining to visualize autoantibody binding patterns in brain tissue sections. The color changes produced by chromogenic substrates reveal the specific neural antigens and brain regions targeted by autoantibodies, providing visual evidence of immune-mediated pathology and helping researchers map the anatomical distribution of autoimmune damage
Solution Approach 2:
The patent employs immunoblotting to detect autoantibodies against specific neural antigens by separating brain proteins by molecular weight and detecting antibody binding patterns. This technique transforms the complex immune response into a readable profile of which specific antigens are targeted, providing quantitative and qualitative information about the autoimmune mechanism underlying neurodevelopmental disorders
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods provide definitive assays for diagnosing neurodevelopmental disorders, allowing for early intervention and predicting the risk of ASD in individuals and their offspring, by identifying autoantibodies and their binding patterns in brain tissues.
Implementation Method 1
determining the presence or absence, or differential presence, of an autoantibody directed against a neural antigen in a sample from an individual having a neurodevelopmental disorder; and detecting a pattern of staining of brain regions and cell types bound by the autoantibody
Data Source
AI summary
The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.